echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Israel's new micro-left adricture monitoring equipment has been identified as groundbreaking

    Israel's new micro-left adricture monitoring equipment has been identified as groundbreaking

    • Last Update: 2021-03-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    , Israel's upstart company Vectorius Medical Technologies announced that its left adricle pressure sensor (V-LAP) has been awarded a breakthrough medical device by the U.S. FDA, which is primarily used to treat heart failure.Heart failure is a chronic disease that affects about 27 million patients worldwide. The V-LAP system is an in-heart micro, battery-free, digital wireless device that can be used to monitor pressure in the left adricle (LAP) and communicate from deep inside the body in a high-resolution waveform form. At present, it has carried out safety and effectiveness assessment in the first human research trial in a multi-center. Vectorius Medical Technologies says LAP has been shown to accurately and effectively predict early heart failure deterioration.Dr William Abraham, a professor at the Ohio State University College school of medicine, said: "The increased hydraulic build-up in the left aricdenosis of the heart can lead to worsening heart failure, which requires hospitalization. With V-LAP, doctors can remotely understand left arical stress, which is potential information and valid data for treating patients with heart failure, especially those with pulmonary hypertension and/or second-tip valve reflow. Remote monitoring of LAP has great potential for development because it keeps patients in good condition and does not require hospitalization. TheVectorius is currently conducting clinical trials in Italy, Germany, the United Kingdom and Israel with a view to CE certification and plans to launch the study in the United States in 2022. (Creative Exchange):. Retrieved 2020-12-02, from[2] Vectorious’ in-heart microcomputer wins FDA breakthrough nod Retrieved 2020-12-02, from
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.